Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5BFL4)

• Drug Name: YM 471 Drug Info
• Synonyms: YM-471

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9810140
  TTD Drug ID: DM5BFL4

Molecule-Related Drug Atlas

Drug(s) Targeting Vasopressin V1b receptor (V1BR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[3]
Mozavaptan	DMZ905C	Hyponatraemia	5C72	Approved	[4]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[5]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[6]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[7]
ABT-436	DMNAU1V	Anxiety disorder	6B00-6B0Z	Phase 2	[8]
ARGENINE VASOPRESSIN	DM8KN0Q	Discovery agent	N.A.	Investigative	[9]
D[Arg4,Orn8]VP	DM8D4QT	Discovery agent	N.A.	Investigative	[9]
D[Leu4,Lys8]VP	DMDBU7Q	Discovery agent	N.A.	Investigative	[9]
D[Arg4,Lys8]VP	DM69OVM	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Vasopressin V2 receptor (V2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[3]
Mozavaptan	DMZ905C	Hyponatraemia	5C72	Approved	[10]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[11]
Tolvaptan	DMIWFRL	Autosomal dominant polycystic kidney disease	GB81	Approved	[12]
Conivaptan	DM1V329	Euvolemic hyponatremia	5C72	Approved	[13]
Vasopressin	DMQ2FPC	Diabetes insipidus	5A61.5	Approved	[14]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[6]
Lixivaptan	DMDN4ZP	Hyponatraemia	5C72	Phase 3	[15]
Satavaptan	DME5PN3	Acute and chronic heart failure	BD1Z	Phase 3	[16]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[17]

Drug(s) Targeting Vasopressin V1a receptor (V1AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[3]
Mozavaptan	DMZ905C	Hyponatraemia	5C72	Approved	[18]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[19]
Conivaptan	DM1V329	Euvolemic hyponatremia	5C72	Approved	[13]
Felypressin	DMHLP9C	Localisation	N.A.	Approved	[20]
Terlipressin	DMT9FH3	Hypertension	BA00-BA04	Approved	[21]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[6]
Balovaptan	DMKMTDG	Autism spectrum disorder	6A02	Phase 3	[22]
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[23]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vasopressin V1a receptor (V1AR)	TT4TFGN	V1AR_HUMAN	Antagonist	[2]
Vasopressin V1b receptor (V1BR)	TTL9MHW	V1BR_HUMAN	Antagonist	[2]
Vasopressin V2 receptor (V2R)	TTK8R02	V2R_HUMAN	Antagonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2205).
• [2] Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol. 2001 Jul;133(5):746-54.
• [3] Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
• [4] New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9.
• [5] The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
• [6] The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
• [7] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [8] The vasopressin Avprlb receptor: Molecular and pharmacological studies. Stress. 2011 January; 14(1): 98-115.
• [9] Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
• [10] Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
• [12] Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84.
• [13] Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23.
• [14] Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9.
• [15] Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
• [16] Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J. 2009 Apr 15;419(2):507-17.
• [17] Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
• [18] Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65.
• [19] Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
• [20] Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
• [21] Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31.
• [22] Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J Med Chem. 2020 Feb 27;63(4):1511-1525.
• [23] Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.